{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:29:02Z","timestamp":1793809742071,"version":"4.6.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.urolonc.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:49:18Z","timestamp":1754405358000},"page":"597.e1-597.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-6307","authenticated-orcid":false,"given":"Ryan D.","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.07.003_bib0001","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0002","article-title":"1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors","volume":"10","author":"Olson","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0003","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-21-2275","article-title":"Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors","volume":"28","author":"Palmer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106126","article-title":"Independent drug action and its statistical implications for development of combination therapies","volume":"98","author":"Chen","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0005","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0006","unstructured":"automeris.Io: computer vision assisted data extraction from charts using WebPlotDigitizer n.d. https:\/\/automeris.io\/(accessed February 10, 2025)."},{"key":"10.1016\/j.urolonc.2025.07.003_bib0007","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0008","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0009","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up\u2606","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0011","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent drug action in combination therapy: implications for precision oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9417","article-title":"Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the US","volume":"7","author":"Mathew Thomas","year":"2024","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0013","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification is frequent in solid tumors and predicts Enfortumab Vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0014","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0016","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","article-title":"Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade","volume":"42","author":"Hamidi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2025.07.003_bib0017","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:28:08Z","timestamp":1757338088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1078143925002558"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}